| Year |
Title |
Altmetric |
| 2021
|
Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis..
American Journal of Hematology.
2021
|
|
| 2021
|
CHIPping away at Erdheim-Chester disease.
Blood.
137:434-436.
2021
|
|
| 2021
|
Acute Pancreatitis from Treatment with BRAF Inhibitors in Erdheim-Chester Disease: A Report from 2 Tertiary Referral Centers.
Pancreas.
50:e6-e8.
2021
|
|
| 2021
|
Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis.
Clinical Lymphoma, Myeloma and Leukemia.
21:e66-e75.
2021
|
|
| 2021
|
Rosai-dorfman disease displays a unique monocyte-macrophage phenotype characterized by expression of OCT2.
American Journal of Surgical Pathology.
45:35-44.
2021
|
|
| 2020
|
Efficacy of BRAF-Inhibitor Therapy in BRAFV600E-Mutated Adult Langerhans Cell Histiocytosis
2020
|
|
| 2020
|
Low-dose vemurafenib monotherapy in BRAFV600E-mutated Erdheim-Chester disease
2020
|
|
| 2020
|
Survival and prognostic factors in patients with rectal squamous cell carcinoma
2020
|
|
| 2020
|
Erdheim-Chester disease: Consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.
Blood.
135:1929-1945.
2020
|
|
| 2020
|
Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival: CA19-9 in the staging of extra-hepatic cholangiocarcinoma
2020
|
|
| 2020
|
Association between facility volume and mortality of patients with classic Hodgkin lymphoma.
Cancer.
126:757-764.
2020
|
|
| 2020
|
43-Year-Old Man With Polyuria and Bone Pain.
Mayo Clinic Proceedings.
95:e13-e18.
2020
|
|
| 2020
|
Erdheim–Chester disease: expanding the spectrum of cutaneous manifestations.
British Journal of Dermatology.
182:405-409.
2020
|
|
| 2020
|
Bone marrow findings in Erdheim-Chester disease: Increased prevalence of chronic myeloid neoplasms
2020
|
|
| 2020
|
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease
2020
|
|
| 2020
|
Erdheim-chester disease with concomitant rosai-dorfman like lesions: A distinct entity mainly driven by MAP2K1
2020
|
|
| 2020
|
The Tissue Issue: When to Biopsy Persistent or Refractory Disease in Classic Hodgkin Lymphoma.
Acta Haematologica.
2020
|
|
| 2019
|
Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin.
British Journal of Haematology.
187:e51-e54.
2019
|
|
| 2019
|
The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease.
Mayo Clinic Proceedings.
94:2054-2071.
2019
|
|
| 2019
|
Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis
2019
|
|
| 2019
|
Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States.
Clinical Lymphoma, Myeloma and Leukemia.
19:441-446.
2019
|
|
| 2019
|
Autoimmune encephalitis secondary to melanoma.
Annals of Internal Medicine.
170:905-906.
2019
|
|
| 2019
|
Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.
Investigational New Drugs.
37:473-481.
2019
|
|
| 2019
|
Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.
Leukemia.
33:1273-1277.
2019
|
|
| 2019
|
Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms.
Blood.
133:1607-1610.
2019
|
|
| 2019
|
A population-based analysis of second primary malignancies in T-cell neoplasms.
British Journal of Haematology.
185:338-342.
2019
|
|
| 2019
|
T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes.
British Journal of Haematology.
185:140-142.
2019
|
|
| 2019
|
Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma
2019
|
|
| 2019
|
Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma
2019
|
|
| 2019
|
Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.
Journal of Gastrointestinal Oncology.
10:554-561.
2019
|
|
| 2019
|
Editorial plasmacytomas: Many faces of one disease, or many diseases with one face?.
Oncotarget.
10:257-258.
2019
|
|
| 2019
|
Improved interpretability of machine learning model using unsupervised clustering: Predicting time to first treatment in chronic lymphocytic leukemia.
JCO Clinical Cancer Informatics.
3.
2019
|
|
| 2018
|
Arterial involvement in Erdheim-Chester disease A retrospective cohort study.
Medicine.
97.
2018
|
|
| 2018
|
Efficacy of biological agents in the treatment of Erdheim-Chester disease.
British Journal of Haematology.
183:520-524.
2018
|
|
| 2018
|
A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
Breast Cancer Research and Treatment.
170:677-685.
2018
|
|
| 2018
|
Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes.
British Journal of Haematology.
182:579-581.
2018
|
|
| 2018
|
Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer.
Lung Cancer.
122:214-219.
2018
|
|
| 2018
|
Florid dermatopathic lymphadenopathy—A morphological mimic of Langerhans cell histiocytosis.
Clinical Case Reports.
6:1637-1638.
2018
|
|
| 2018
|
Treatment approaches and outcomes in plasmacytomas: Analysis using a national dataset.
Leukemia.
32:1414-1420.
2018
|
|
| 2018
|
Neuroradiologic manifestations of Erdheim-Chester disease.
Neurology: Clinical Practice.
8:15-20.
2018
|
|
| 2018
|
Contemporary management of localized resectable pancreatic cancer.
Cancers.
10.
2018
|
|
| 2018
|
Histiocytic sarcoma: A population-based analysis of incidence, demographic disparities, and long-term outcomes.
Blood.
131:265-268.
2018
|
|
| 2017
|
Clinical and radiological responses to oral methotrexate alone or in combination with other agents in erdheim-chester disease.
Blood Cancer Journal.
7.
2017
|
|
| 2017
|
Treatment Patterns and Outcomes in Early-stage Hodgkin Lymphoma in the Elderly: A National Cancer Database Analysis.
Clinical Lymphoma, Myeloma and Leukemia.
17:812-818.
2017
|
|
| 2017
|
Clinical and radiologic responses to cladribine for the treatment of Erdheim-Chester disease.
JAMA Oncology.
3:1253-1256.
2017
|
|
| 2017
|
Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: Analysis using a national data set.
Blood Cancer Journal.
7.
2017
|
|
| 2016
|
Composite lymphoma with diffuse large B-cell lymphoma and classical Hodgkin lymphoma components: A case report and review of the literature
2016
|
|
| 2016
|
Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target.
Familial Cancer.
15:359-366.
2016
|
|
| 2016
|
Acquired haemophilia A: An unusual postoperative complication.
BMJ Case Reports.
2016.
2016
|
|
| 2016
|
Trends in Use of Radiation Therapy for Hodgkin Lymphoma from 2000 to 2012 on the Basis of the National Cancer Data Base.
Clinical Lymphoma, Myeloma and Leukemia.
16:12-17.
2016
|
|
| 2015
|
Salivary gland cancers: Biology and systemic therapy
2015
|
|
| 2015
|
L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.
Future Oncology.
11:2459-2470.
2015
|
|
| 2015
|
Double-Hit Lymphoma.
Journal of Clinical and Experimental Hematopathology.
55:51-53.
2015
|
|
| 2015
|
Multicentric Castleman Disease with Monoclonal Incomplete IgH Restriction: A Rare Coexistence.
Journal of Clinical and Experimental Hematopathology.
55:103-108.
2015
|
|
